A Cohort Study on the Immunogenicity and Safety of the Inactivated SARS-CoV-2 Vaccine (BBIBP-CorV) in Patients With Breast Cancer; Does Trastuzumab Interfere With the Outcome?
Open Access
- 1 March 2022
- journal article
- research article
- Published by Frontiers Media SA in Frontiers in Endocrinology
- Vol. 13, 798975
Abstract
Aim: To determine the efficacy and safety of inactivated SARS-CoV-2 vaccine (BBIBP-CorV) in patients with breast cancer.Methods: In this multi- institutional cohort study, a total of 160 breast cancer patients (mean age of 50.01 ± 11.5 years old) were assessed for the SARS-CoV-2 Anti-Spike IgG and SARS-CoV2 Anti RBD IgG by ELISA after two doses of 0.5 mL inactivated, COVID-19 vaccine (BBIBP-CorV). All patients were followed up for three months for clinical COVID-19 infection based on either PCR results or imaging findings. Common Terminology Criteria for Adverse Events were used to assess the side effects.Results: The presence of SARS-CoV-2 anti-spike IgG, SARS-CoV2 anti-RBD IgG, or either of these antibodies was 85.7%, 87.4%, and 93.3%. The prevalence of COVID-19 infection after vaccination was 0.7%, 0% and 0% for the first, second and third months of the follow-up period. The most common local and systemic side-effects were injection site pain and fever which were presented in 22.3% and 24.3% of patients, respectively.Discussion: The inactivated SARS-CoV-2 vaccine (BBIBP-CorV) is a tolerable and effective method to prevent COVID-19.Keywords
Funding Information
- Sabzevar University of Medical Sciences
This publication has 49 references indexed in Scilit:
- Therapeutic potential of pharmacological TGF-β signaling pathway inhibitors in the pathogenesis of breast cancerBiochemical Pharmacology, 2019
- Lymphocyte depletion and repopulation after chemotherapy for primary breast cancerBreast Cancer Research, 2016
- Cancer statistics in China, 2015CA: A Cancer Journal for Clinicians, 2016
- Assessment of the prognostic and predictive utility of the Breast Cancer Index (BCI): an NCIC CTG MA.14 studyBreast Cancer Research, 2016
- The immune system and response to HER2-targeted treatment in breast cancerThe Lancet Oncology, 2014
- Phase III Study of Doxorubicin/Cyclophosphamide With Concomitant Versus Sequential Docetaxel As Adjuvant Treatment in Patients With Human Epidermal Growth Factor Receptor 2–Normal, Node-Positive Breast Cancer: BCIRG-005 TrialJournal of Clinical Oncology, 2011
- Prevalence of Antibodies to Four Human Coronaviruses Is Lower in Nasal Secretions than in SerumClinical and Vaccine Immunology, 2010
- Examination of seroprevalence of coronavirus HKU1 infection with S protein-based ELISA and neutralization assay against viral spike pseudotyped virusJournal of Clinical Virology, 2009
- Trastuzumab after Adjuvant Chemotherapy in HER2-Positive Breast CancerNew England Journal of Medicine, 2005
- Influence of adjuvant hormone therapy and chemotherapy on the immune system analysed in the bone marrow of patients with breast cancer.2003